An open-label study to assess the effect of combination treatment with Avastin [bevacizumab] and Xeloda [capecitabine], plus pre-operative standard radiotherapy, on response rate in patients with locally advanced rectal cancer

Trial Profile

An open-label study to assess the effect of combination treatment with Avastin [bevacizumab] and Xeloda [capecitabine], plus pre-operative standard radiotherapy, on response rate in patients with locally advanced rectal cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2014

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Fluorouracil; Folinic acid
  • Indications Rectal cancer
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 08 Sep 2011 Actual end date is April 2011 as reported by ClinicalTrials.gov.
    • 08 Sep 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top